Breaking News, Collaborations & Alliances

Mission Bio Transfers Tapestri GMP-Ready CGT Assay to Avance Biosciences

Marks a key milestone for Tapestri’s ability to power single-cell analysis in clinical trial settings for cell & gene therapies.

Author Image

By: Charlie Sternberg

Associate Editor

Mission Bio, a pioneer in high-throughput single-cell DNA and multi-omics analysis, has completed its first tech transfer of a clinical trial-ready cell and gene therapy (CGT) assay from its Tapestri Platform to Avance Biosciences Inc., a CRO based in Houston, Texas, to assess transduction efficiency for an autologous cell therapy currently under development.   This collaboration marks the first time the Tapestri Platform will undergo qualification and validation within a good manufacturing pr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters